Explore the complex interplay between advanced nanotechnology and biomedical innovation, focusing on the transformative potential of LNPs in developing precise and effective therapeutic interventions in this free webinar.
Join us March 25 at 10 a.m. CT: https://bit.ly/3MJ6RiV
Exciting new addition to the Empowering Patients Summit! 📢 Join us for a live Q&A with ASGCT CEO David Barrett as he dives into the Society’s newest initiatives. Register for the free virtual Summit (March 11–12 and on demand): asgct.org/empowering
Congrats to Danaher Corporation, @ahrensnicklas.bsky.social, @kiranmusunuru.bsky.social, and @urnov.bsky.social! This group has been awarded the 2026 Catalyst Award for the extraordinary collaborative effort behind a first-of-its-kind personalized CRISPR gene-editing therapy: https://bit.ly/3MLe5Tt
Two new expert-led Content Collections are now live in the ASGCT Learning Center. Master the art of communication with The Scientist’s Writing Toolkit or deepen your technical knowledge with our Viral Vectors collection.
Free for ASGCT members! Start learning today: https://learning.asgct.org/
The February edition of The Patient Press is here! 🦓 From showing our stripes on #RareDiseaseDay to major policy wins like the PRV program reauthorization, we’re honoring the milestones that move the needle for patients: https://bit.ly/3MUvbON
Meet the winners of the 2026 ASGCT Honorific Awards! This year, we are thrilled to recognize 17 distinguished leaders who are making a profound impact to advance the field of cell and gene therapy.
Read the full announcement and learn more about our winners: https://bit.ly/4aQZi1C
Join our upcoming regulatory webinar to de-risk your PPQ campaign. We’re breaking down how to identify common gaps, mitigate risks, and build a clear roadmap for high-quality CGT production: https://www.asgct.org/events-meetings/ppq-readiness-what-to-know-before-starting-a-ppq-campaign
The 2026 #NORDSymposium takes place April 14-15, 2026 in Arlington, VA. This event connects
scientific and medical patient advocacy leaders with clinicians and researchers across rare diseases
to support research readiness, trial design, and progress for patients. https://nordscience.org/
Take your expertise to the next level with the ASGCT Learning Center! From engaging coursework to expert-led content collections, we have resources for every stage of your CGT career.
💻 Start learning: https://www.asgct.org/education-career-resources/asgct-learning-center
ASGCT recently submitted comments to the OSTP highlighting the need for robust NIH funding, flexible CMC pathways, and improved public-private collaboration to advance cell and gene therapies.
Read our full policy recommendations: https://bit.ly/3OoVBIS
“Having a genetic diagnosis, it’s not the end. This is a powerful piece of information that can help guide next steps.” Hear Kim Nye, founder of TESS Research Foundation, and genetic counselor Dr. Lauren Beretich in our latest Community Quick Take: https://bit.ly/4tztTsP
📢 LAST CALL: Don’t miss out on the lowest price for the ASGCT 2026 Annual Meeting! Your deadline to save expires at midnight. Register now: https://annualmeeting.asgct.org/register-attend/rates-registration?utm_campaign=AM26&utm_source=bluesky&utm_medium=social&utm_content=1771432222
We’re looking for high-impact, newsworthy science to take the stage in Boston this May! Submit your late-breaking abstract today: https://annualmeeting.asgct.org/abstracts/submission-information/late-breaking-abstracts
The Empowering Patients Summit is just one month away! RSVP to secure your spot at this free, virtual event: asgct.org/empowering
Congress nears completion of FY26 appropriations with modest #NIH increase (~$415M) and stable ARPA-H funding at $1.5B. Critically, F&A cost reimbursement rates preserved for research institutions. Read more in The Advocate: https://bit.ly/3OyPsK1
#ASGCTAdvocacy #ResearchFunding
In our latest episode of The Issue, Melissa Majerol (CMMI Model Lead) breaks down the Cell and Gene Therapy Access Model and its initial rollout for sickle cell disease. 🎧 Listen in for a deep dive into the model’s current status and its impact on the CGT landscape: https://bit.ly/4r2e7oH
The latest Gene, Cell, & RNA Therapy Landscape Report is now available! While the final quarter of 2025 was marked by significant regulatory milestones, it also illustrated a broader recalibration of the early-stage pipeline. 🔗 Read the full Q4 report: asgct.org/landscape-report
Every cancer journey is unique, and cell and gene therapies are at the forefront of personalized care. This #WorldCancerDay, deepen your understanding of the field with on-demand content from our Advancing Cell + Gene Therapies for Cancer conference: https://learning.asgct.org/courses/113807
🚨 FINAL CALL: Don't let your groundbreaking research miss its opportunity to be showcased to the global cell and gene therapy community! Submit by 8 p.m. ET: https://annualmeeting.asgct.org/abstracts/submission-information
What does it take for patient groups to move a gene therapy from the lab to the clinic? Join Kim Nye, Michelle Krueger, and Joe Katakowski at the Empowering Patients Summit on March 11 for a deep dive into the realities of patient-led drug development: https://bit.ly/3LS2QIt
📢 #ASGCT2026 Abstract Deadline: TOMORROW, Feb. 3 at 8 p.m. ET: https://annualmeeting.asgct.org/abstracts/submission-information
As January comes to an end, we’re reflecting on a major year for #ASGCTAdvocacy! Read our 2025 recap: https://www.asgct.org/news-publications/asgct-news/advancing-cgts-in-2025-asgcts-policy-and-advocacy-highlights
MORE TIME TO SUBMIT! ⏳ We’ve extended the #ASGCT2026 abstract deadline to Feb. 3 at 8 p.m. ET. Submit now: https://annualmeeting.asgct.org/abstracts/submission-information
Book your hotel for #ASGCT2026 through our official block today! Stay in the heart of Boston's biotech hub with maximum flexibility and our best rate guarantee.
Take advantage of our early registration discount before it’s gone: https://annualmeeting.asgct.org/register-attend/travel-accommodation
ASGCT is proud to lead nonprofits, academic medical centers, and patient advocacy groups in urging Congress to pass the Mikaela Naylon Give Kids a Chance Act and reauthorize the Rare Pediatric Disease Priority Review Voucher Program: https://bit.ly/4sZ2alh
Deadline: January 30 ⏱️ Don't miss out on the opportunity to present your groundbreaking work #ASGCT2026! Submit your abstract: https://annualmeeting.asgct.org/abstracts/submission-information
Ever wonder how gene editing actually works? 🤔 From CRISPR to base editing, the science is moving fast—and we’re here to help you make sense of it all. https://patienteducation.asgct.org/understanding-cell-gene-therapy/types-of-cell-gene-therapy/gene-editing
⏱️ It's time to finalize your #ASGCT2026 abstract. Hit that submit button today! https://annualmeeting.asgct.org/abstracts/submission-information
ASGCT launches CGTxchange to rescue shelved therapies, urges Senate action on PRV reauthorization, and provides critical updates on federal funding and FDA manufacturing programs.
Read more in the latest edition of The Advocate: https://bit.ly/45ItIkK
Don't miss out on the opportunity to present your groundbreaking work at this essential gathering of cell and gene therapy professionals. Submit your abstract today! https://annualmeeting.asgct.org/abstracts/submission-information
